Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lenvima is a prescription kinase inhibitor containing lenvatinib. Current U.S. labeling includes locally recurrent or metastatic progressive radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and selected advanced endometrial carcinoma.
read more about lenvima ...Lenvatinib inhibits receptor tyrosine kinases involved in angiogenesis and tumor growth, including vascular endothelial growth factor receptors, fibroblast growth factor receptors, RET, KIT, and platelet-derived growth factor receptor alpha.
Lenvima is used alone for selected differentiated thyroid cancer and unresectable hepatocellular carcinoma. It is combined with pembrolizumab for first-line advanced renal cell carcinoma and selected advanced endometrial carcinoma. It is combined with everolimus for advanced renal cell carcinoma after one prior anti-angiogenic therapy.
Differentiated thyroid cancer uses 24 mg once daily. First-line advanced renal cell carcinoma uses 20 mg once daily with pembrolizumab. Previously treated renal cell carcinoma uses 18 mg once daily with everolimus. Unresectable hepatocellular carcinoma uses 12 mg daily for body weight of at least 60 kg and 8 mg daily below 60 kg. Advanced endometrial carcinoma uses 20 mg once daily with pembrolizumab.
Serious concerns include hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, kidney failure or impairment, proteinuria, diarrhea, fistula or gastrointestinal perforation, QT prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhage, thyroid dysfunction, impaired wound healing, osteonecrosis of the jaw, and embryo-fetal toxicity.
Current labeling includes selected differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
The recommended dose is 24 mg once daily.
The dose is 12 mg once daily for patients weighing at least 60 kg and 8 mg once daily for patients weighing less than 60 kg.
Yes. Current labeling includes Lenvima with pembrolizumab for first-line advanced renal cell carcinoma and selected advanced endometrial carcinoma.
DailyMed - LENVIMA (lenvatinib) capsule and kit. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e. Date Accessed October 8, 2026.
Lenvatinib. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a615015.html. Date Accessed October 8, 2026.
Lenvatinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lenvatinib. Date Accessed October 8, 2026.
Lenvima. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lenvima. Date Accessed October 8, 2026.
LENVIMA (lenvatinib) Prescribing Information. Eisai. https://www.lenvima.com/-/media/Project/EISAI/Lenvima/PDF/prescribing-information.pdf. Date Accessed October 8, 2026.